Literature DB >> 32889674

Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields.

Willem J Koemans1,2,3, Ruben T H M Larue4,5, Maximilian Kloft2, Jessica E Ruisch2, Inge Compter4, Robert G Riedl6, Lara R Heij7,8, Wouter van Elmpt4, Maaike Berbée4, Jeroen Buijsen4, Philippe Lambin5, Meindert N Sosef1, Heike I Grabsch9,10.   

Abstract

BACKGROUND: The presence of lymph node metastasis (LNmets) is a poor prognostic factor in oesophageal cancer (OeC) patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery. Tumour regression grade (TRG) in LNmets has been suggested as a predictor for survival. The aim of this study was to investigate whether TRG in LNmets is related to their location within the radiotherapy (RT) field.
METHODS: Histopathological TRG was retrospectively classified in 2565 lymph nodes (LNs) from 117 OeC patients treated with nCRT and surgery as: (A) no tumour, no signs of regression; (B) tumour without regression; (C) viable tumour and regression; and (D) complete response. Multivariate survival analysis was used to investigate the relationship between LN location within the RT field, pathological TRG of the LN and TRG of the primary tumour.
RESULTS: In 63 (54%) patients, viable tumour cells or signs of regression were seen in 264 (10.2%) LNs which were classified as TRG-B (n = 56), C (n = 104) or D (n = 104) LNs. 73% of B, C and D LNs were located within the RT field. There was a trend towards a relationship between LN response and anatomical LN location with respect to the RT field (p = 0.052). Multivariate analysis showed that only the presence of LNmets within the RT field with TRG-B is related to poor overall survival.
CONCLUSION: Patients have the best survival if all LNmets show tumour regression, even if LNmets are located outside the RT field. Response in LNmets to nCRT is heterogeneous which warrants further studies to better understand underlying mechanisms.

Entities:  

Keywords:  Lymph node regression; Neoadjuvant chemoradiotherapy; Oesophageal cancer; Radiation field

Mesh:

Year:  2020        PMID: 32889674      PMCID: PMC7794105          DOI: 10.1007/s10388-020-00777-y

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  25 in total

1.  7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction.

Authors:  Thomas W Rice; Eugene H Blackstone; Valerie W Rusch
Journal:  Ann Surg Oncol       Date:  2010-07       Impact factor: 5.344

2.  A note on quantifying follow-up in studies of failure time.

Authors:  M Schemper; T L Smith
Journal:  Control Clin Trials       Date:  1996-08

Review 3.  Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.

Authors:  G Tomasello; F Petrelli; M Ghidini; E Pezzica; R Passalacqua; F Steccanella; L Turati; G Sgroi; S Barni
Journal:  Eur J Surg Oncol       Date:  2017-03-18       Impact factor: 4.424

4.  Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.

Authors:  William H Allum; Sally P Stenning; John Bancewicz; Peter I Clark; Ruth E Langley
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

5.  Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience.

Authors:  Bin Li; Haiquan Chen; Jiaqing Xiang; Yawei Zhang; Chenguang Li; Haichuan Hu; Yang Zhang
Journal:  J Thorac Cardiovasc Surg       Date:  2012-08-11       Impact factor: 5.209

6.  Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.

Authors:  Maarten C J Anderegg; Sjoerd M Lagarde; Vamshi P Jagadesham; Suzanne S Gisbertz; Arul Immanuel; Sybren L Meijer; Maarten C C M Hulshof; Jacques J G H M Bergman; Hanneke W M van Laarhoven; S Michael Griffin; Mark I van Berge Henegouwen
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

7.  Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.

Authors:  A R Davies; D Myoteri; J Zylstra; C R Baker; W Wulaningsih; M Van Hemelrijck; N Maisey; W H Allum; E Smyth; J A Gossage; J Lagergren; D Cunningham; M Green
Journal:  Br J Surg       Date:  2018-07-26       Impact factor: 6.939

8.  Endosonography for preoperative locoregional staging of esophageal and gastric cancer.

Authors:  H Grimm; K F Binmoeller; K Hamper; J Koch; D Henne-Bruns; N Soehendra
Journal:  Endoscopy       Date:  1993-03       Impact factor: 10.093

Review 9.  Tumour heterogeneity and the evolution of polyclonal drug resistance.

Authors:  Rebecca A Burrell; Charles Swanton
Journal:  Mol Oncol       Date:  2014-07-10       Impact factor: 6.603

10.  Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.

Authors:  Tomohiro Kadota; Ken Hatogai; Tomonori Yano; Takeo Fujita; Takashi Kojima; Hiroyuki Daiko; Satoshi Fujii
Journal:  Cancer Sci       Date:  2018-05-03       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.